| NCT06462794 | First In Human Study of CX-801 in Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-08-28 | 2029-06-30 | 2028-02-28 |
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-04-02 | 2029-03-31 | 2027-11-30 |
| NCT05387265 | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | TERMINATED | PHASE1 | 2022-05-16 | 2025-06-04 | 2025-06-04 |
| NCT04596150 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | COMPLETED | PHASE2 | 2020-12-29 | 2023-06-02 | 2023-06-02 |
| NCT03706274 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | WITHDRAWN | PHASE1 | 2020-01 | 2022-12 | 2020-12 |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | TERMINATED | PHASE2 | 2019-11-20 | 2020-05-21 | 2020-05-21 |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | COMPLETED | PHASE1, PHASE2 | 2018-06-15 | 2023-06-01 | 2023-06-01 |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2017-06-01 | 2020-09-10 | 2020-09-10 |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | TERMINATED | PHASE1, PHASE2 | 2017-01-19 | 2020-10-27 | 2020-10-27 |